joining you we Thanks, provide third quarter. us on for this afternoon Alex. an Thank update as the
Emily. heard and and me our with As CFO, the provide clinical will today be Marcio will on you development call updates. and Marcio commercial COO
Additionally, Emily financials. QX will provide update on our
to In platforms. multiple our this diversified mission we biotech have company with advance fully quarter, continued of integrated creating a
by diversified rare and as anticipate we internal that development, previously our our and well multiple to company described a strategic in disorder $X.X have have billion products business we leading the is will as As platforms revenue approximately both we combination XXXX. vision through scientific innovative using programs of be
of to and out this will the we number executing of discuss building are in our efforts continue a across company we programs. how Today vision
presented competitive results World risdiplam. the clinical highlighted continued seen review Society the advantage benefits will also and Muscle that the with during We
Latin Portuguese founders the ANVISA. effect. opportunity Tegsedi important to this Along patients. with Latin the of approximately I’m with in approved The Portuguese X,XXX we hATTR largest have is successfully worldwide by achieved Brazil in October, ancestry, disease in in marks with one second because markets proud to treat approval America the report Translarna America was year. Brazil the that that with this largest country is has a in
has Tegsedi injection often by of are in high infusion in saturated America access. that advantage a is Additionally, need or Through seeing to hard the access being early subcutaneous delivered unmet Latin our we medical America. as are there Latin programs, centers
educate gain identifying the that the initiate patients medicine. us giving these of launch, to approval The will ensuring We on outreach. have community importance opportunity for allow to direct Tegsedi’s physician the and patients continued access us to ANVISA
have also been grow our We DMD continuing franchise. to
line in in As year quarter revenues million combined $XX.X third top we hear when of of will quarter about reported the million. detail, you to of previous third $XX XXXX more this commercial compared
with nonsense also We is a Translarna. from which first STRIVE quarter, this due international Registry have results to receiving registry patients for mutation the shared DMD the
our in rare compound select inflammation. it pivotal combination for late-stage is used asset a regulation to to disorders be potential BioElectron trials portfolio. will targets of ready integrated our enzyme to be existing I’m pipeline. be from key The the into with required the and also asset in Corporation that announce stress a in pleased involved CNS Technology have we has in oxidative that and This programs
disorders. We after exciting because pay that agreed is and have of believe CNS regulatory treating rare novel one opportunity an milestones this due approvals. to the certain are We approach success anti-inflammatory based year of
programs our like in to gene now therapy. I to turn
report that gene the submission. therapy to we the AADC year manufacturing therapy by FDA happy product successfully the for have gene the end the mentioned, previously As we for BLA we on to a required completed to AADC our submit track run of are program. necessary BLA of I’m
file an for following plan Europe also We MAA AADC to in to deficiency the our FDA. submission
to one the programs therapy gene are launch position of potentially in worldwide. to a first We proud be
more discuss As efforts to patients’ a we have position good will in finding with detail, year. Marcio you ramped our next to this in for be expect up have launch strong a and product
to Our Friedreich’s program therapy in gene continues ataxia move forward.
of expect manufacturing now mid year. timelines, clinic we next However, to the enter because
our gears update switch you to been splicing now the using me we’ve on progress Let making platform.
that information and Roche of the is FIREFISH Foundation SMA on and well. At the shared for progressing the SMA from Muscle milestones we are clinical risdiplam been and Our that have with SUNFISH treatment improvement are Meeting, not pivotal otherwise studies. collaboration would beginning that the babies observing we World updated very Recently achieved. including walk reported stand. have These continued Society SMA demonstrated patients to
from Additionally, risdiplam to tolerated no well events. adverse continues with dropouts be reported
to has that studied Given a all for a broad include SMA next to approval cohort year. SMA been risdiplam patients, be expect a for broad launch in potential of we label would patients a
therefore, all small selectively is, affected We anticipate important systemic, the of widely SMA and be types gene bioavailable to shown drug has in program be of validating protein. used is This patients. splicing SMN that that is is been first SMA our molecule The lack splicing the orally leads to that to that this is goes affecting to expression, the modulating molecule small the first that that all platform. tissues
disease on as success that disorders. treat to other platform patients And In the potential effects two from diseases. have treat to that programs program, treat FD. identified that treat this or Huntington to the dysautonomia One HD. we splicing to have identified our Based of particular, modulators discussed have other compound program patients suffering or is used identify to selectively, have splicing from that specifically orphan familial we suffering was to molecules disease splicing impacts
Ashkenazi This a hundred in population patients defect only the an discuss these an molecule Jewish patient the a PTCXXX FD. Israel, is the a shown I resulting predominantly disorder bioavailable corrects orally U.S., population. potent few in splicing with been in that now is effectively of highly mutation will programs. and has from ultra-orphan that splicing founders’ small found
not the clinical The development trial require point, and path this patient or FDA is forward we At discontinued This us decisions complex is this we a that trial. program. have indicated long two difficult recently and population. make this allows of FD not years small a in would there development, development design Unfortunately, feasible greater have drug to path FD. placebo-controlled as that such move to in in
and disappointed are patients their We families the suffer familial dysautonomia. for from that
ultra-rare would rare for move advocate to in continue the community the allow to diseases to disorders difficult work for disease will with forward. We process regulatory that
now to Let switch program. our me HD discuss
focused splicing are tissues We are reduction program. on and shown highly HD have the as be HTT Huntington’s as selective mouse The rapidly the of well compounds protein it shown brain all other it model. to modifiers in areas in advancing the identified our of exciting,
performing GLP We production safety in process the of toxicology. GMP are now compound larger to of scale perform one HD
is the Huntington’s disease and blood to distribution deliver all bring to program bioavailable advantages are strong brain. broad an rapidly, to XXXX. expect systemic will enter in the program the us that to is advancing a through landscape. Like and a in of therapeutic the SMA, has continue will orally We disease having that systemically compound delivered Huntington’s tissues simple that including there number competitive the As we believe is clinic that the tissues, in advantage
As number milestones you can up. coming have see, we a exciting of
look be at an will time. We sharing we information that on on Day X pipeline March more hosting Analyst and forward detailed to our
Marcio? he can Marcio, turn so to to clinical call and commercial the provide at over PTC. the like programs I’d on update an development
